1. Home
  2. CELC vs JJSF Comparison

CELC vs JJSF Comparison

Compare CELC & JJSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • JJSF
  • Stock Information
  • Founded
  • CELC 2011
  • JJSF 1971
  • Country
  • CELC United States
  • JJSF United States
  • Employees
  • CELC N/A
  • JJSF N/A
  • Industry
  • CELC Medical Specialities
  • JJSF Specialty Foods
  • Sector
  • CELC Health Care
  • JJSF Consumer Staples
  • Exchange
  • CELC Nasdaq
  • JJSF Nasdaq
  • Market Cap
  • CELC 2.3B
  • JJSF 1.9B
  • IPO Year
  • CELC 2017
  • JJSF N/A
  • Fundamental
  • Price
  • CELC $50.51
  • JJSF $96.80
  • Analyst Decision
  • CELC Strong Buy
  • JJSF Buy
  • Analyst Count
  • CELC 6
  • JJSF 2
  • Target Price
  • CELC $63.00
  • JJSF $142.50
  • AVG Volume (30 Days)
  • CELC 1.0M
  • JJSF 192.2K
  • Earning Date
  • CELC 11-13-2025
  • JJSF 11-12-2025
  • Dividend Yield
  • CELC N/A
  • JJSF 3.22%
  • EPS Growth
  • CELC N/A
  • JJSF N/A
  • EPS
  • CELC N/A
  • JJSF 4.29
  • Revenue
  • CELC N/A
  • JJSF $1,599,746,000.00
  • Revenue This Year
  • CELC N/A
  • JJSF $3.57
  • Revenue Next Year
  • CELC N/A
  • JJSF $2.70
  • P/E Ratio
  • CELC N/A
  • JJSF $22.58
  • Revenue Growth
  • CELC N/A
  • JJSF 0.49
  • 52 Week Low
  • CELC $7.58
  • JJSF $94.13
  • 52 Week High
  • CELC $63.06
  • JJSF $180.80
  • Technical
  • Relative Strength Index (RSI)
  • CELC 49.45
  • JJSF 33.24
  • Support Level
  • CELC $44.42
  • JJSF $94.13
  • Resistance Level
  • CELC $52.76
  • JJSF $99.14
  • Average True Range (ATR)
  • CELC 3.10
  • JJSF 2.29
  • MACD
  • CELC -1.11
  • JJSF 0.06
  • Stochastic Oscillator
  • CELC 51.39
  • JJSF 26.73

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About JJSF J & J Snack Foods Corp.

J&J Snack Foods Corp manufactures, markets, and distributes snack foods and beverages to foodservice and retail supermarket outlets. The company's products include frozen beverages, juice, fruit bars, sorbet, cakes, and cookies that are distributed to various consumers, including restaurants, supermarkets, convenience stores, universities, theaters, and theme parks. The company operates in three business segments: food service, which sells snacks, desserts, and baked goods at the point-of-sale; retail supermarkets, which sells frozen and prepackaged products to supermarkets; and frozen beverages, which sells frozen beverages under brands Icee, Slush puppie, and Parrot ice in the United States, Mexico, and Canada.

Share on Social Networks: